Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
Beth Faiman, Jason Valent Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA Abstract: Improved understanding as to the biology of multiple myeloma (MM) and the bone marrow microenvironment has led to the development of new drugs to...
Guardado en:
Autores principales: | Faiman B, Valent J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0849c85822d74002822d0eaab3b3a1d7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
por: Bhutani D, et al.
Publicado: (2017) -
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
por: Gupta VA, et al.
Publicado: (2021) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Angelo Maiolino, et al.
Publicado: (2021) -
Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum A, et al.
Publicado: (2018) -
Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
por: Edvan de Queiroz Crusoé, et al.
Publicado: (2021)